JNJ Quantitative Stock Analysis

Johnson & Johnson (JNJ) received an 88% rating from Validea's P/B Growth Investor model, a strategy by Partha Mohanram focused on identifying low book-to-market stocks with sustained future growth potential. As a large-cap growth stock in the Biotechnology & Drugs sector, JNJ largely satisfies the model's fundamental criteria, passing most tests but notably failing on Research and Development to Assets. This high score indicates significant interest from a growth investment perspective, consistent with Mohanram's market-outperforming growth research.

Analysis

Johnson & Johnson (JNJ) has been identified as a strong candidate under Validea's P/B Growth Investor model, achieving a high score of 88%. This model, based on research by Partha Mohanram, specifically targets low book-to-market stocks that exhibit strong indicators of sustained future growth. The analysis shows JNJ, a large-cap in the Biotechnology & Drugs industry, passing on nearly all fundamental criteria, including return on assets, cash flow from operations, and stability in both sales and ROA. This suggests robust operational efficiency and financial health. However, a critical point of concern is the model's 'FAIL' rating for JNJ on the 'Research and Development to Assets' metric. For a company operating in a heavily innovation-driven sector, this could signal a potential weakness in its long-term growth pipeline relative to its asset base, a factor that contrasts with the otherwise positive fundamental picture.

Key Decisions for Investors

• Investors with a growth-oriented mandate should consider the 88% model score as a strong quantitative signal, supported by JNJ's positive performance on key metrics like ROA and cash flow.
• The failure on the Research and Development to Assets metric warrants further due diligence; investors should closely monitor JNJ's R&D spending and pipeline developments in upcoming quarters to assess long-term competitive positioning.
• This analysis is particularly relevant for those employing a 'Growth at a Reasonable Price' (GARP) framework, as the model's focus on low book-to-market stocks with strong fundamentals aligns with that investment style.